Related Experiment Videos
Editor-in-Chief's welcome to Hepatology, Medicine and Policy
1CHIP, Centre for Health and Infectious Disease Research and WHO Collaborating Centre on HIV and Viral Hepatitis, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Insights
Hepatology, Medicine, and Policy (HMAP) is a new journal addressing viral hepatitis and other liver diseases. It aims to unify biomedical and social science approaches for better liver health outcomes.
Area of Science:
- Hepatology
- Medicine
- Public Health Policy
Background:
- Viral hepatitis, alcohol-associated liver disease, and non-alcoholic fatty liver disease pose significant global health challenges.
- Recent progress in viral hepatitis treatment highlights the need for a comprehensive approach to liver health.
- Existing efforts often lack a unified strategy, necessitating an integrated platform for diverse research.
Discussion:
- Hepatology, Medicine, and Policy (HMAP) is launched to bridge the gap between clinical science and policy.
- The journal will publish research spanning public health, social sciences, and clinical medicine.
- It aims to foster a multidisciplinary dialogue on liver disease prevention, management, and health equity.
Key Insights:
- HMAP will publish articles on epidemiology, economics, health behavior, ethics, and human rights related to liver disease.
- The journal emphasizes the role of laws, policies, and clinical guidelines in shaping health initiatives.
- It seeks to integrate biomedical and social science perspectives for a holistic understanding of liver health.
Outlook:
- The emergence of advanced hepatitis C treatments presents a timely opportunity to address broader liver health issues.
- HMAP is committed to advancing research and policy to improve global liver health outcomes.
- The journal endeavors to be a leading platform for impactful research in hepatology and related fields.
Abstract:
Hepatology, Medicine and Policy (HMAP), a new open-access peer-reviewed journal, is making its debut at a time when the hepatitis field is seeing great progress but still has far to go. The World Health Organization and many countries have shown increasing interest in viral hepatitis in recent years, helping to foster a stronger response to this group of diseases. Meanwhile, alcohol-associated cirrhosis and alcohol-associated liver cancer continue to take a heavy toll worldwide, as does non-alcoholic fatty liver disease. The lack of a unified strategic response to viral hepatitis and other liver diseases is the impetus for launching HMAP, which will publish policy, public health and social science articles alongside clinical science articles. It will encourage submissions in diverse domains such as disease prevention and management, epidemiology, economics, health behavior, health service delivery, ethics, human rights, and the role of laws, policies and clinical guidelines in shaping health initiatives. The current attention to powerful new hepatitis C treatments presents a strategic opportunity to more comprehensively address the full constellation of biomedical and social issues relating to liver health. HMAP is committed to publishing research and policy articles that help to drive forward this broader agenda.